LifeBond enrolling patients in LifeSeal surgical sealant study: 4 key notes

Caesarea, Israel-based LifeBond is enrolling patients in the United States and Western Europe for its LifeSeal Surgical Sealant’s IDE clinical trial.

Advertisement

Here’s what you should know.

1. LifeBond partnered with 20 medical centers to enroll patients into the study.

2. LifeBond will announce an additional 20 clinical sites soon.

3. Several Western European countries commercially use LifeSeal, which earned a CE Mark in April 2016.

4. The gastrointestinal-facing sealant provides reinforcement and minimize staple-line leakage.

More articles on gastroenterology:
GI leader to know: Dr. Ismail Wadiwala of Sutter Health
RedHill Biopharma’s Bekinda phase III study treats last patient: 4 things to know
Cantel Medical to acquire distributor’s endoscopy business assets: 3 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.